和元生物
(688238)
| 流通市值：44.37亿 | | | 总市值：44.91亿 |
| 流通股本：6.41亿 | | | 总股本：6.49亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 180,353,622.06 | 119,854,988.98 | 52,847,732.33 | 248,149,229.12 |
| 营业收入 | 180,353,622.06 | 119,854,988.98 | 52,847,732.33 | 248,149,229.12 |
| 二、营业总成本 | 341,998,749.46 | 223,076,169.16 | 114,041,714.68 | 528,959,440.25 |
| 营业成本 | 210,558,408.32 | 136,974,595.98 | 72,106,725.07 | 341,969,512.89 |
| 税金及附加 | 5,382,392.63 | 3,592,008.5 | 1,792,808.02 | 6,481,244.35 |
| 销售费用 | 34,008,390.45 | 21,898,993.78 | 10,953,143.72 | 51,708,237.86 |
| 管理费用 | 53,167,973.99 | 34,960,817.22 | 17,523,088.67 | 81,077,032.15 |
| 研发费用 | 34,661,199.52 | 23,213,376.93 | 10,820,956.46 | 47,329,777.21 |
| 财务费用 | 4,220,384.55 | 2,436,376.75 | 844,992.74 | 393,635.79 |
| 其中:利息费用 | 5,985,745.11 | 3,729,024.87 | 1,666,025.62 | 7,454,794.3 |
| 其中:利息收入 | 1,840,835.95 | 1,332,758.26 | 843,164.67 | 7,321,394.49 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 86,487.4 | 84,032.41 | -175,080.28 | 259,112.69 |
| 加:投资收益 | -237,379.9 | -306,068.54 | 796,552.09 | 3,577.44 |
| 资产处置收益 | -1,069,405.85 | -879,106.69 | -55,663.77 | 5,900,892.14 |
| 资产减值损失(新) | -415,032.39 | -509,253.14 | 146,223.62 | -55,507,906.49 |
| 信用减值损失(新) | -1,330,413.03 | -1,108,011.64 | -308,245.25 | 522,774.74 |
| 其他收益 | 4,822,026.87 | 3,466,199.44 | 1,704,432.55 | 19,180,950.3 |
| 四、营业利润 | -159,788,844.3 | -102,473,388.34 | -59,085,763.39 | -310,450,810.31 |
| 加:营业外收入 | 0.25 | 0.25 | 0.11 | 23,969.29 |
| 减:营业外支出 | 342,370.5 | 298,252.59 | 398,243.31 | 2,200,275.88 |
| 五、利润总额 | -160,131,214.55 | -102,771,640.68 | -59,484,006.59 | -312,627,116.9 |
| 减:所得税费用 | 1,886,172.63 | 1,709,529.1 | 26,251.79 | 9,555,233.43 |
| 六、净利润 | -162,017,387.18 | -104,481,169.78 | -59,510,258.38 | -322,182,350.33 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -162,017,387.18 | -104,481,169.78 | -59,510,258.38 | -322,182,350.33 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -162,113,304.23 | -104,570,120.7 | -59,477,301.44 | -321,813,001.26 |
| 少数股东损益 | 95,917.05 | 88,950.92 | -32,956.94 | -369,349.07 |
| 扣除非经常损益后的净利润 | -162,228,230.91 | -104,511,833.71 | -59,592,746.41 | -335,912,406.82 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.25 | -0.16 | -0.09 | -0.5 |
| (二)稀释每股收益 | -0.25 | -0.16 | -0.09 | -0.5 |
| 八、其他综合收益 | 2,085,099.25 | 2,124,667.76 | 883,401.49 | -1,303,608.23 |
| 归属于母公司股东的其他综合收益 | 2,085,099.25 | 2,124,667.76 | 883,401.49 | -1,303,608.23 |
| 九、综合收益总额 | -159,932,287.93 | -102,356,502.02 | -58,626,856.89 | -323,485,958.56 |
| 归属于母公司股东的综合收益总额 | -160,028,204.98 | -102,445,452.94 | -58,593,899.95 | -323,116,609.49 |
| 归属于少数股东的综合收益总额 | 95,917.05 | 88,950.92 | -32,956.94 | -369,349.07 |
| 公告日期 | 2025-10-28 | 2025-08-19 | 2025-04-24 | 2025-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |